Phloridzin (phlorizin)

Phloridzin is a dihydrochalcone compound that selectively inhibits sodium-glucose co-transporters SGLT1 and SGLT2, blocking glucose absorption in the intestines and kidneys. This mechanism promotes glucose excretion through urine and may support blood sugar management.

Origin & History

Phloridzin is a dihydrochalcone flavonoid glucoside naturally found in apple tree bark and leaves (Malus domestica) and other Rosaceae family plants. It is extracted through crystallization as a dihydrate from water or synthesized via glucosylation of phloretin through NADPH-dependent pathways.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the available research. Phloridzin is primarily noted as a plant metabolite without references to traditional medicine systems.

Health Benefits

• Glucose absorption inhibition through SGLT1/SGLT2 blockade (preclinical evidence only)
• Potential glycosuria promotion for blood sugar management (mechanism established, human trials absent)
• Antioxidant properties (mechanistic studies only)
• Enhanced transepithelial water permeability similar to aquaporins (in vitro evidence)
• Competitive inhibition of intestinal glucose uptake (animal models only)

How It Works

Phloridzin competitively inhibits sodium-glucose co-transporters SGLT1 in the small intestine and SGLT2 in the kidney proximal tubules, preventing glucose reabsorption. This blockade forces glucose excretion through urine (glycosuria) and reduces postprandial blood glucose levels. The compound also exhibits antioxidant activity through free radical scavenging mechanisms.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted with phloridzin as a therapeutic agent. Available research focuses exclusively on preclinical models and mechanistic studies of SGLT transporter inhibition (referenced PMIDs 20980548, 34880492 describe SGLT mechanisms but not phloridzin trials).

Clinical Summary

Current evidence for phloridzin is limited to preclinical studies and mechanistic research in animal models. No human clinical trials have evaluated phloridzin supplementation for blood sugar management or other health outcomes. While the SGLT1/SGLT2 inhibition mechanism is well-established in laboratory studies, human efficacy data is absent. The compound's safety profile and effective dosing ranges in humans remain undetermined.

Nutritional Profile

Phloridzin (phlorizin) is a dihydrochalcone flavonoid compound, not a macronutrient source — it contains no meaningful protein, fat, fiber, or caloric content at physiologically relevant doses. Molecular formula: C21H24O10; molecular weight: 436.4 g/mol. It is a glycoside composed of phloretin (aglycone) linked to glucose via a beta-glycosidic bond. Naturally occurring concentrations: apple tree bark (up to 4–10% dry weight), apple leaves (~0.5–2% dry weight), apple roots (highest density, up to 10–12% dry weight), apple flesh and peel (trace amounts, 0.005–0.02 mg/g fresh weight). Crabapple species contain notably higher concentrations than commercial Malus domestica cultivars. As a bioactive compound, typical experimental doses range from 0.1–500 mg/kg body weight in preclinical models. Oral bioavailability is limited (~10–20% estimated) due to hydrolysis by intestinal lactase-phlorizin hydrolase (LPH) converting it to phloretin and glucose; phloretin itself is more readily absorbed. Phloretin plasma half-life approximately 2–4 hours in rodent models. No significant micronutrient content. Solubility: moderately soluble in water (~0.5 g/L at 25°C), better solubility in ethanol and methanol. Stability is pH-dependent with degradation accelerating above pH 8.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are lacking. Preclinical research uses it as an SGLT inhibitor tool compound, but no standardized forms (extract, powder) or human dosing data exist. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium, Cinnamon extract, Alpha-lipoic acid, Bitter melon, Gymnema sylvestre

Safety & Interactions

Safety data for phloridzin supplementation in humans is lacking due to absence of clinical trials. Potential concerns include excessive glucose loss through urine, which could lead to dehydration or electrolyte imbalances. The compound may theoretically interact with diabetes medications, particularly SGLT2 inhibitors like empagliflozin, potentially causing additive glucose-lowering effects. Pregnant and breastfeeding women should avoid phloridzin due to insufficient safety data.